Identification of risk factors for nephrotoxicity in patients receiving extended-duration, high-trough vancomycin therapy.

ABSTRACT:

Background

In the past, impurities in vancomycin formulations were thought to contribute to nephrotoxicity. In contrast, when current, purer formulations are dosed at conventional trough levels (i.e., 5-15 mg/L), the incidence of nephrotoxicity is relatively low. Recent guidelines have recommended targeting higher vancomycin trough levels in treatment of complicated methicillin-resistant Staphylococcus aureus infections. Dosing based on these higher trough levels may be associated with nephrotoxicity, so the potential risk factors for vancomycin-associated nephrotoxicity require clearer definition.

Objectives

To determine the occurrence of nephrotoxicity in patients receiving more than 7 days of vancomycin therapy with high trough levels (15-20 mg/L) and to identify and eval

SUBMITTER: Contreiras C 

PROVIDER: S-EPMC4006757 | biostudies-literature | 2014 Mar

REPOSITORIES: biostudies-literature